找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Kala Azar in South Asia; Current Status and S E. Noiri,T.K. Jha Book 2016Latest edition Springer International Publishing 2016 Neglected Tr

[復(fù)制鏈接]
樓主: Malicious
31#
發(fā)表于 2025-3-26 23:28:14 | 只看該作者
http://image.papertrans.cn/k/image/541720.jpg
32#
發(fā)表于 2025-3-27 04:54:16 | 只看該作者
33#
發(fā)表于 2025-3-27 08:30:17 | 只看該作者
linical, epidemiological and entomological aspects.Includes .Visceral leishmaniasis (VL), (also known as black fever or Kala-azar) is a life-threatening disease?first reported from the Indian subcontinent. VL ranks as the world’s second largest parasitic disease killer and is a neglected tropical di
34#
發(fā)表于 2025-3-27 10:07:26 | 只看該作者
35#
發(fā)表于 2025-3-27 14:47:47 | 只看該作者
36#
發(fā)表于 2025-3-27 20:43:45 | 只看該作者
Vaccine Development for Leishmaniasisalian hosts, enabling a multilateral prevention strategy. Furthermore, the use of a vaccine is now not only for prevention but also for treatment. Within this manuscript we review background information, the current status, and the future direction of vaccine development for leishmaniasis.
37#
發(fā)表于 2025-3-27 23:53:48 | 只看該作者
Potentiality of Urinary L-FABP Tests to Kala-Azar Disease Managementrinary immuno-chromatography dipstick test for point of care use in endemic areas. We expect that a FABP1 dipstick test will serve as a triage marker in disease monitoring of VL. In addition, this chapter introduces the impact of FABP1 on predicting survival in septic acute kidney injury and the clinical interpretation of FABP1 measurements in VL.
38#
發(fā)表于 2025-3-28 04:42:45 | 只看該作者
39#
發(fā)表于 2025-3-28 09:04:20 | 只看該作者
40#
發(fā)表于 2025-3-28 12:11:39 | 只看該作者
Changes of , Antigens in Kala-Azar Patients’ Urine After Treatment than that with nested PCR (88 %), but higher than that with KAtex (48 %) before the treatment, and it reduced more slowly than that with the others after the treatment. As the urine ELISA gives CA levels quantitatively, it will be useful to evaluate the efficacy of the treatments used and for surveillance of drug resistance.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 19:03
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
新蔡县| 孟村| 平泉县| 天长市| 沅陵县| 电白县| 商城县| 城步| 太康县| 萨嘎县| 曲阳县| 原平市| 古浪县| 蕲春县| 兰西县| 田阳县| 兰溪市| 南投县| 眉山市| 陈巴尔虎旗| 大港区| 临高县| 灵丘县| 水城县| 稷山县| 朝阳市| 剑阁县| 武强县| 漳浦县| 湟中县| 东城区| 翁牛特旗| 南溪县| 十堰市| 日土县| 定日县| 红桥区| 新龙县| 西吉县| 台东市| 永寿县|